Atrasentan in Patients With Proteinuric Glomerular Diseases
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety
of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive
loss of renal function.